帕罗西汀和盐酸舍曲林治疗脑卒中后抑郁的临床疗效及安全性评价

Clinical efficacy and safety of paroxetine hydrochloride and sertraline hydrochloride in the treatment of post-stroke depression

目的比较盐酸帕罗西汀与盐酸舍曲林治疗脑卒中后抑郁的临床疗效及安全性。方法将60例脑卒中后抑郁患者随机分为试验组28例和对照组32例。试验组给予盐酸帕罗西汀20 mg·d-1口服治疗,对照组给予盐酸舍曲林50mg·d-1口服治疗,疗程均为12周。比较2组患者治疗12周后的临床疗效、汉密尔顿抑郁量表(HAMD)和美国国立卫生研究院卒中量表(NIHSS)评分及巴塞尔指数变化情况及不良反应发生率。结果试验组临床总有效率89.29%,对照组93.75%,差异无统计学意义(P>0.05)。治疗12周后,2组HAMD、NIHSS及巴塞尔指数评分较治疗前均显著下降(P<0.05),但是2组治疗12周末上述评分差异均无统计学意义(P>0.05)。试验组不良反应总发生率21.43%,对照组18.75%,差异无统计学意义(P>0.05)。结论盐酸帕罗西汀与盐酸舍曲林治疗脑卒中后抑郁的临床疗效相当,不良反应均较为轻微。

Objective To compare the clinical efficacy of paroxetine hydrochloride and sertraline hydrochloride in the treatment of post -stroke depression.Methods Sixty patients diagnosed with post -strke depression were recruited in this study and randomized divided into treat-ment group （ n=28 ） and control group （ n=32 ） .Patients in the treat-ment group were given paroxetine hydrochloride 20 mg· d-1 orally and patients in the control group were given sertraline hydrochloride 50 mg· d-1 orally.The treatment lasted for 12 weeks.The Hamilton rating scale for depression （ HAMD ） , National institute of health stroke scale （ NIHSS） and barthel index （ BI） were evaluated in every two weeks after the treatment.The score of HAMD, NIHSS, BI and adverse drug reac-tions were recorded and compared between the two groups .Results The clinical efficacy were 89.29% and 93.75% in the treatment group and control group respectively , without statistical difference （ P〉0.05 ） .The score of HAMD , NIHSS and BI were significantly decreased after 12 weeks treatment in both groups （ P〈0.05 ）.But the scores at the end of the 12 weeks were not statistically different between the two groups （ P〉0.05 ） . The incidence of adverse drug reactions were 21.43% and 18.75% in the treatment group and control group respectively with no statistical difference （ P〉0.05 ） .Conclusion No statistical differencein clinical efficacy and safety were found between paroxetine hydrochloride and sertraline hydrochloride in the treatment of post-stroke depression , both with low incidence of adverse drug reactions .